Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine disease that is observed frequently to be related to increased insulin resistance. The use of insulin-sensitizer compounds, such as metformin, permits great improvement of such metabolic abnormality and the restoration of normal ovarian function. Metformin administration reduces insulin resistance and androgen production both from the ovary and adrenal gland. AIM: On this basis we aimed to evaluate a group of non-obese amenorrheic PCOS patients before and after 6 months of metformin administration (500 mg per os twice daily) to better understand what changes might be induced by metformin on adrenal and ovarian function and in terms of temporal coupling of the pulsatile profiles of luteinizing hormone (LH), cortisol and allopregnanolone, the latter representative of the neurosteroid family. METHOD: A group of non-obese PCOS patients (n = 8) was enrolled after informed consent and underwent to a pulsatility study for LH, cortisol and allopregnanolone, and an oral glucose tolerance test before and on day 7 of the first menstrual cycle occurring after the 5th month of treatment. RESULTS: Plasma androgen levels were decreased significantly by metformin treatment, as were plasma LH and allopregnanolone levels and insulin resistance. Metformin administration decreased LH pulse amplitude but not pulse frequency. On the contrary, cortisol and allopregnanolone showed a significant change in pulse frequency. When temporal coupling was tested between pulsatile profiles of LH or cortisol with allopregnanolone, cortisol pulses were temporally coupled to allopreganolone peaks both before and under metformin administration while LH pulses were temporally coupled to allopreganolone secretory peaks only under metformin treatment. CONCLUSIONS: Our data demonstrate that metformin administration modulates LH secretion as well as cortisol and allopregnanolone pulsatile release. In addition, the results demonstrate that adrenal and ovarian steroidogenic activity is greatly modulated by any change in insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 1×
“Metformin is a water-soluble oral biguanide that is usually administered in type 2 diabetes mellitus to enhance insulin sensitivity in liver and muscle tissue, where it improves glucose uptake and use [5,6] with no direct effect on insulin secretion by pancreatic cells [7,8].”
BackgroundVelazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“The present study demonstrated that, in the absence of any change of BMI, metformin administration is able to modulate not only gonadotropin and androgen secretions as previously reported [5,18,32,33,35], but also allopregnanolone secretion.”
BackgroundInsulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus
Ovalle, F., & Azziz, R. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03111-4 · Cited by 428 · cited 1×
“Moreover, a great many PCOS patients (50–70%) are affected by insulin resistance and hyperinsulinemia [4].”
BackgroundNeurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain
Mellon, S. H., & Deschepper, C. F. (1993) · Brain Research · doi:10.1016/0006-8993(93)91332-m · Cited by 398
Sensitization to Insulin Induces Ovulation in Nonobese Adolescents with Anovulatory Hyperandrogenism
Ibáñez, L., Valls, C., Ferrer, A., Marcos, M. V., Rodriguez-Hierro, F., & de Zegher, F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7756 · Cited by 162
Cited by
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: Insight from animal models
Roland, A. V., & Moenter, S. M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.04.002 · Cited by 57
“It also has been shown in multiple studies to reduce the LH pulse amplitude in non-obese PCOS patients (Genazzani et al., 2006, 2004), suggesting a possible reduction in GnRH release.”
MethodUse of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Self-citation
Metadata
- Authors
- Genazzani, A. D., Strucchi, C., Luisi, M., Casarosa, E., Lanzoni, C., Baraldi, E., Ricchieri, F., Mehmeti, H., & Genazzani, A. R.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 22
- Issue
- 1
- Pages
- 36-43
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2079729898
- Cited by
- 36
- References
- 5
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. https://app.cochat.ai/papers/10.1080/09513590500476164
- The paper
- Genazzani, A. D., Strucchi, C., Luisi, M., Casarosa, E., Lanzoni, C., Baraldi, E., Ricchieri, F., Mehmeti, H., & Genazzani, A. R. (2006). Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecological Endocrinology. https://doi.org/10.1080/09513590500476164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.